Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

The company narrowed its full-year sales guidance range, saying it now expects sales in the range of $64.3 billion to $65.3 ...

Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.

The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

Merck (NYSE:MRK) on Tuesday reported second-quarter earnings and revenue that beat and missed analyst expectations, respectively, while narrowing its outlook for the year.

Drugmaker Merck & Co on Tuesday announced job and cost cuts it said will save $3 billion a year as it posted lower ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Plunging sales of Merck’s blockbuster HPV vaccine in China have caused a sharp fall in the US pharma group’s earnings. In ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...